If you’ve been keeping up, you may remember hearing last year about Letybo (LetibotulinumtoxinA), the newest FDA-approved neuromodulator designed to treat glabellar lines. While official release date hasn’t been announced, there’s buzz around its arrival in the U.S., with some practitioners, like Dr. Chad Deal of Southern Surgical Arts, reporting that they’ve already received shipments of the product.
With this development, we wanted to provide medspa owners and staff with the information you need to stay informed about what Letybo could mean for your practice and clients.
What is Letybo?
Letybo is a botulinum toxin type A injectable manufactured by Hugel, a South Korean pharmaceutical company. It has been marketed internationally under the brand name Nabota and is already used in over 40 countries. With its recent FDA approval in February 2024, Letybo is now entering the competitive U.S. neuromodulator market, joining established brands like Botox, Dysport, Xeomin, and Jeuveau.
Dr. Deal’s recent Instagram post confirms that Letybo is already being distributed to select practices, signaling that broader availability may not be far behind.
Key Details About Letybo
Pricing Positioning
One of the most talked-about aspects of Letybo is its pricing strategy.
- Industry insiders suggest that Letybo will be priced 10-20% lower than Botox.
While exact costs haven’t been confirmed, this potential price difference could make it an appealing option for medspas looking to offer more affordable treatments or improve profit margins.
Efficacy and Results
Clinical trials indicate that Letybo effectively reduces glabellar lines for 3-4 months , which is consistent with other neuromodulators on the market. For medspas, this means it could serve as a comparable alternative to existing options without requiring significant changes to treatment protocols.
Global Track Record
Letybo’s international presence under the name Nabota gives it a strong foundation. Its success in markets like South Korea—a global leader in beauty innovation—may appeal to clients who value cutting-edge treatments and K-beauty trends.
Availability and Rollout
While Letybo’s official rollout timeline hasn’t been announced, Dr. Deal’s Instagram post suggests that distribution is already underway. This indicates that broader availability for medspas may happen sooner than expected. Practices interested in offering Letybo should stay tuned for updates on training programs, distributor partnerships, and launch details.
Final Thoughts: Staying Informed
As always, our goal is to provide medspa owners and staff with the latest information to help you make informed decisions for your practice. The introduction of Letybo highlights the rapidly evolving nature of the aesthetics industry, where innovation and competition continue to expand treatment options.
Whether Letybo becomes a staple in your medspa or simply serves as another tool in your arsenal, staying informed about new products and trends is key to navigating this dynamic market.
